Abstract 3930
Background
Tepotinib is an oral, selective, potent MET tyrosine kinase inhibitor, with promising clinical activity in patients (pts) with MET+ tumors, being tested in NSCLC harboring METex14 mutations or MET amplification. We aimed to further characterize the safety profile of tepotinib.
Methods
Safety data from pts receiving tepotinib 500 mg once daily (QD) from five studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992) were pooled and summarized. Pts received tepotinib until disease progression, intolerable toxicity, or other withdrawal. Adverse events (AEs) were graded by NCI CTCAE v4.03.
Results
As of 9/28/2018, 422 pts had received tepotinib; 228 received 500 mg tepotinib monotherapy QD and were further analyzed for safety (73.2% male, 50.9%/35.5% white/Asian, median age 65.0 [range 19–89] yrs). Median treatment duration was 2.7 months (range 0.0–21.5); in NSCLC pts with METex14 mutations it was 4.1 months (NCT02864992). 219 pts (96.1%) had an AE (any cause). 122 pts (53.5%) had a Grade ≥3 any cause AE including (>3.5%): disease progression (n = 18, 7.9%), hyponatremia (n = 12, 5.3%), increased aspartate aminotransferase (AST) (n = 12, 5.3%), increased lipase (n = 11, 4.8%), peripheral edema (n = 9, 3.9%) and ascites (n = 9, 3.9%). The incidence rates were: 19.0, 12.9, 12.9, 12.0, 9.6 and 9.6 per 100 pt-years, respectively. Treatment-related (TR)AEs are shown in the Table. 18 pts (7.9%) had a serious TRAE including (≥1%) peripheral edema (n = 4, 1.8%). AEs (any cause) led to dose reduction of tepotinib in 33 pts (14.5%) and discontinuation in 49 pts (21.5%), and was due to peripheral edema in 5 (8.5%) and 7 (3.1%) pts, respectively. Of 25 AEs leading to death, two were considered treatment related by the investigator (upper GI hemorrhage and hypoglycemic coma).
Conclusions
Tepotinib demonstrated an acceptable safety profile across a range of tumor types and is being developed in NSCLC as monotherapy and in combination. Further characterization of peripheral edema is ongoing.Table:
479P
N = 228 | ||
---|---|---|
Any Grade (≥10%) | Grade ≥3 (≥2%) | |
Any TRAE, n (%) | 172 (75.4) | 52 (22.8) |
Peripheral edema | 77 (33.8) | 8 (3.5) |
Diarrhea | 45 (19.7) | 4 (1.8) |
Fatigue | 34 (14.9) | 3 (1.3) |
Nausea | 29 (12.7) | 0 (0) |
Decreased appetite | 27 (11.8) | 0 (0) |
Increased lipase | 13 (5.7) | 9 (3.9) |
Increased AST | 11 (4.8) | 5 (2.2) |
Clinical trial identification
NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.
Editorial acknowledgement
Medical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Matthew deSchoolmeester, PhD of Bioscript Science (Macclesfield, UK).
Legal entity responsible for the study
Merck KGaA.
Funding
Merck KGaA.
Disclosure
T. Decaens: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: IPSEN; Honoraria (self), Travel / Accommodation / Expenses: Gilead; Honoraria (self), Travel / Accommodation / Expenses: Abbvie; Honoraria (self): Sanofi; Advisory / Consultancy: SITEX; Research grant / Funding (institution): ArQule; Research grant / Funding (institution): Genoscience Pharma; Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy: BTG; Advisory / Consultancy: Sirtex. R. Veillon: Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Merck. K. Yamazaki: Honoraria (self): Chugai; Honoraria (self): Takeda; Honoraria (self): Yakult; Honoraria (self): Daiichi‐sankyo; Honoraria (self): Merck Serono; Honoraria (self): Bristol; Honoraria (self): Bayer; Honoraria (self): Eli Lilly; Honoraria (self): Taiho; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Sanofi. J. Scheele: Full / Part-time employment: Merck KGaA. R. Bruns: Full / Part-time employment: Merck KGaA. K. Berghoff: Full / Part-time employment: Merck KGaA. S. Faivre: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Blueprint; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer Pharma; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis. P.P. Paik: Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Abbvie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Celgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: EMD Serono; Honoraria (self): Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract